<DOC>
	<DOCNO>NCT02735980</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy prexasertib give participant extensive stage disease small cell lung cancer ( ED-SCLC ) . The study evaluate body process drug drug affect body . The study also evaluate association tumor response participant 's perceive quality life .</brief_summary>
	<brief_title>A Study Prexasertib ( LY2606368 ) Participants With Extensive Stage Disease Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Have EDSCLC receive prior platinumbased regimen Participants Cohort 1 must objective response prior platinumbased therapy subsequent progression â‰¥90 day last dose platinum Participants Cohort 2 must either objective response prior platinum base therapy progression &lt; 90 day last dose platinum Have performance status 0 1 Eastern Cooperative Oncology Group scale Have receive 2 prior therapy EDSCLC ( include immunotherapy , targeted therapy , chemotherapy ) Have symptomatic central nervous system ( CNS ) malignancy metastasis . Asymptomatic participant treat CNS metastasis eligible study currently receive corticosteroid treat CNS metastasis Have previously complete withdrawn study study investigate prexasertib checkpoint kinase I ( CHK1 ) inhibitor show hypersensitivity component prexasertib formulation Have serious cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>SCLC</keyword>
	<keyword>LY2606368</keyword>
	<keyword>CHK1</keyword>
</DOC>